Wall Street brokerages expect TapImmune Inc. (NASDAQ:MRKR) to post earnings of ($0.13) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for TapImmune’s earnings. TapImmune reported earnings of ($0.41) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 68.3%. The firm is scheduled to report its next earnings results on Thursday, August 8th.

According to Zacks, analysts expect that TapImmune will report full year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.58) to ($0.53). For the next financial year, analysts anticipate that the business will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.75) to ($0.39). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover TapImmune.

TapImmune (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05.

Several brokerages have recently commented on MRKR. WBB Securities upgraded shares of TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 price objective on the stock in a report on Friday, March 29th. Janney Montgomery Scott began coverage on shares of TapImmune in a report on Friday, March 1st. They issued a “buy” rating and a $6.22 price objective on the stock. Finally, Zacks Investment Research lowered shares of TapImmune from a “buy” rating to a “hold” rating in a report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $9.25.

Shares of MRKR stock opened at $5.72 on Monday. The company has a current ratio of 19.73, a quick ratio of 22.11 and a debt-to-equity ratio of 0.01. TapImmune has a one year low of $3.33 and a one year high of $13.55. The company has a market capitalization of $260.17 million, a PE ratio of -3.43 and a beta of -0.03.

A hedge fund recently bought a new stake in TapImmune stock. Personal Capital Advisors Corp bought a new position in shares of TapImmune Inc. (NASDAQ:MRKR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,712 shares of the company’s stock, valued at approximately $143,000. Personal Capital Advisors Corp owned approximately 0.06% of TapImmune as of its most recent SEC filing. 34.47% of the stock is owned by institutional investors.

About TapImmune

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

Read More: What are the most popular ETFs

Get a free copy of the Zacks research report on TapImmune (MRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.